Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is characterized by high protein binding and primarily biliary excretion.
## Primary Indications
Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required (regardless of stage, including ESRD).
* **Hepatic Impairment:** No dose adjustment required.
## Contraindications
* History of hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin secretagogues or insulin).
* **Serious:** Pancreatitis (including fatal cases), severe and disabling arthralgia, bullous pemphigoid, hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin exposure, reducing efficacy. Consider alternative anti-diabetic therapy if efficacy is suboptimal.
* **Insulin/Insulin Secretagogues (e.g., Sulfonylureas):** May increase risk of hypoglycemia; a lower dose of the secretagogue or insulin may be required.
## Monitoring
* **Hemoglobin A1c (HbA1c):** Primarily every 3–6 months.
* **Blood Glucose:** Periodic self-monitoring of blood glucose.
* **Clinical Signs:** Monitor for symptoms of pancreatitis (e.g., persistent severe abdominal pain) and worsening skin lesions (bullous pemphigoid).
## Clinical Pearls
* **Non-Renal Clearance:** Linagliptin is the only DPP-4 inhibitor that does not require dose adjustments for renal impairment, making it a favorable choice in patients with chronic kidney disease.
* **Administration:** May be taken with or without food.
* **Pancreatitis Risk:** Discontinue promptly if pancreatitis is suspected. Do not restart if confirmed.
* **Heart Failure:** While not explicitly contraindicated, use caution in patients with heart failure due to increased reports of heart failure hospitalization observed with other DPP-4 inhibitors (e.g., saxagliptin).
***
**Disclaimer:** This information is for educational purposes only. Clinical practice protocols and prescribing information may vary by region or institution. Always consult the latest official manufacturer prescribing information and local clinical guidelines before prescribing or administering medication.
